Not yet a member?
Print This Post
view / write comments
Here is the first podcast of what we plan will be an ongoing series of round table discussions with cancer experts about real case scenarios and how we make decisions in practice. My guests for the discussion are Drs. Janessa Laskin, medical oncologist from British Columbia Cancer Agency in Vancouver, BC, and Alan Sandler, medical oncologist and Director of Hematology/Oncology at Oregon Health & Science University in Portland.
The first case we discussed is a relatively young Asian never-smoking woman with an advanced lung adenocarcinoma, focusing first on the changing standards for sending tissue for molecular testing, as well as the limitations of that. Here is the video version, audio, transcript, and associated figures.
round-table-laskin-sandler-never-smoker-mutn-testing-audio-podcast
round-table-laskin-sandler-never-smoker-mutn-testing-transcript
round-table-laskin-sandler-never-smoker-mutn-testing-figures
The case continues with the next podcast, discussing first-line chemotherapy-based treatment options and maintenance therapy. Look for that next week.
I’ve completed several initial podcasts with colleagues from around the country just over the last few weeks, using largely my own cases. However, as I mentioned in an earlier post, we are happy to consider your own cases and questions if you would like to submit them and have questions that are timely and potentially relevant to a broad audience in the cancer community. So if you’re interested, please e-mail a brief synopsis and perhaps your central question(s) to west@cancergrace.org for consideration.
Podcast: Play in new window | Download
Related posts:
Related posts brought to you by Yet Another Related Posts Plugin.
Posted in: Clinical Cases, EGFR mutations and other molecular markers, Epidermal growth factor receptor (EGFR)-based therapies, GRACEcast, Gene Profiles/Molecular Signatures, Lung Cancer, Treatment, never-smoker NSCLC email to a friend
Print This Post
Terrific — bring ‘em on!
Ned
1 Comment
Login (Must Be Logged In To Comment)